SCHEMBL7189869

SCHEMBL7189869

Cc1cc(C)c(C(=O)C(C(=O)OCC(C)CC(C)(C)C)c2ccccc2)c(C)c1C.O=[PH3]

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP8 P22894 1/20 0.36
EGFR P00533 2/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
KMT2A Q03164 1/20 0.31
LMNA P02545 2/20 0.31
GAA P10253 1/20 0.31
HTT P42858 1/20 0.31
ATM Q13315 2/20 0.30
KDM4E B2RXH2 1/20 0.30
ALDH1A1 P00352 2/20 0.30
CA12 O43570 1/20 0.30
CA1 P00915 1/20 0.30
CA2 P00918 1/20 0.30
CA9 Q16790 1/20 0.30
TAS1R3 Q7RTX0 1/20 0.30
TAS1R1 Q7RTX1 1/20 0.30
TSHR P16473 2/20 0.30
ADRB2 P07550 1/20 0.30
ADRB1 P08588 1/20 0.30
ADRB3 P13945 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7189842 0.90 MMP8 (0.37) MMP8EGFRL3MBTL1KMT2ALMNA
SCHEMBL7180422 0.89 MMP8 (0.36) MMP8EGFRL3MBTL1LMNAATM
SCHEMBL7186433 0.87 L3MBTL1 (0.40) MMP8EGFRL3MBTL1ATMKDM4E
SCHEMBL7184509 0.87 ALDH1A1 (0.42) MMP8L3MBTL1KMT2ALMNAGAA
SCHEMBL7189306 0.85 MMP8 (0.51) MMP8L3MBTL1KMT2AGAACA12
SCHEMBL7175973 0.83 L3MBTL1 (0.36) MMP8L3MBTL1KMT2ALMNAGAA
SCHEMBL7183225 0.82 L3MBTL1 (0.36) MMP8L3MBTL1KMT2ALMNAGAA
SCHEMBL7182755 0.82 NPC1 (0.36) MMP8EGFRKMT2ALMNAALDH1A1
SCHEMBL7187321 0.82 SLC22A1 (0.40) MMP8L3MBTL1HTTKDM4EALDH1A1
SCHEMBL7182476 0.81 MMP8 (0.42) MMP8L3MBTL1LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 MMP8 4404/4885EGFR 1722/4885L3MBTL1 302/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 MMP8 4586/4885EGFR 2348/4885L3MBTL1 126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.